Abstract
Drug delivery to select therapeutic targets for precision oncology has always been a major challenge in oncology. Anti–body drug conjugates (ADC) and radiopharmaceuticals attempt to overcome the major limitations of chemotherapy or mono-clonal antibody therapy as they provide a highly specific means of attacking the vulnerability of the cancer cell. Currently there are over 100 clinical trials in various stages of development with these agents. Years of improved understanding of ADC technology and addressing previous failures have yielded the current pipeline of ADCs with better design. The near future of ADC developmental therapeutics includes firstly continuing to improve drug design, secondly picking right targets, thirdly balancing efficacy vs toxicity, fourth understanding innate and acquired resistance mechanisms, fifth development of ADCs across pan-cancers as tissue-agnostic therapeutics, and lastly combination strategies. There is considerable excitement in the ADC developmental therapeutics and ADCs including radiopharmaceuticals are here to stay and offer to expand our pipeline of effective drugs to combat cancer.
Original language | English (US) |
---|---|
Article number | 100799 |
Journal | Current Problems in Cancer |
Volume | 45 |
Issue number | 5 |
DOIs | |
State | Published - Oct 2021 |
Keywords
- ADC
- Antibody drug conjugates
- Payload
- Radiophamaceuticals
- Therapeutics
- Warhead
ASJC Scopus subject areas
- Oncology
- Cancer Research